Single-cell and bulk RNA sequencing reveals Anoikis related genes to guide prognosis and immunotherapy in osteosarcoma

• Published in: Scientific reports Vol. 13; no. 1; p. 20203
• Main Authors: Zhong, Cheng, Yang, Dongliang, Zhong, Liping, Xie, Weixing, Sun, Guodong, Jin, Daxiang, Li, Yuming
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18.11.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 692/53; 692/699/67; Anoikis; Anoikis - genetics; Bone cancer; Bone Neoplasms - genetics; Bone Neoplasms - therapy; Chemotherapy; CXCL13 protein; Decision making; Genes; Humanities and Social Sciences; Humans; Immune response; Immunotherapy; Medical prognosis; Metastases; multidisciplinary; Nomograms; Osteosarcoma; Osteosarcoma - genetics; Osteosarcoma - therapy; Patients; Prognosis; Risk groups; Sarcoma; Science; Science (multidisciplinary); Sensitivity analysis; Western blotting
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-47367-3

Anoikis resistance, a notable factor in osteosarcoma, plays a significant role in tumor invasion and metastasis. This study seeks to identify a distinct gene signature that is specifically associated with the anoikis subcluster in osteosarcoma. Clinical, single-cell, and transcriptional data from TARGET and GEO datasets were used to develop a gene signature for osteosarcoma based on the anoikis subcluster. Univariate Cox and LASSO regression analyses were employed. The signature's predictive value was evaluated using time-dependent ROC and Kaplan–Meier analyses. Functional enrichment analyses and drug sensitivity analyses were conducted. Validation of three modular genes was performed using RT-qPCR and Western blotting. Signature (ZNF583, CGNL1, CXCL13) was developed to predict overall survival in osteosarcoma patients, targeting the anoikis subcluster. The signature demonstrated good performance in external validation. Stratification based on the signature revealed significantly different prognoses. The signature was an independent prognostic factor. The low-risk group showed enhanced immune cell infiltration and improved immune function. Drug sensitivity analysis indicated efficacy of chemotherapy agents. Prognostic nomograms incorporating the signature provided greater predictive accuracy and clinical utility. Signatures related to the anoikis subcluster play a significant role in osteosarcoma progression. Incorporating these findings into clinical decision-making can improve osteosarcoma treatment and patient outcomes.